Relaxin: reproductive safeguard turned cardiac?

<span class="paragraphSection"><strong>This editorial refers to ‘Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy’ by J. Nonhoff<span style="font-style:italic;">et al</span>., pp. 598 –608 and ‘Reperfusion therapy with recombinant human relaxin-2 (serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischaemia/reperfusion injury via eNOS-dependent mechanism’ by J. Valle Raleigh<span style="font-style:italic;">et al</span>., pp.<strong><a href="article.aspx?volume=&page=">609 –619<span></span></a></strong>.</strong></span>
Source: Cardiovascular Research - Category: Cardiology Source Type: research